Fludarabine
Epithelial Ovarian Cancer
Beijing BiotechSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 73/ 100
Competitive context
244 Active assets in the Epithelial Ovarian Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Trabectedin AGO Research GmbH | Phase 4 | BBB |
Mirvetuximab Soravtansine AstraZeneca | Phase 3 | BBB |
Olaparib Imunon | Phase 4 | BB |
Irinotecan OHSU Knight Cancer Institute | Phase 2 | BB |
Carboplatin University of Washington | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →